Methicillin-resistant Staphylococcus Aureus Market Size Is Estimated to reach US$ 1,327.9 Million By 2027

SEATTLE, March 25, 2021, (PHARMIWEB) — Methicillin-resistant Staphylococcus Aureus (MRSA) can be classified into two types, based on the mode of infection; hospital-associated MRSA infection (HA-MRSA) and community-associated MRSA infections (CA-MRSA). Various antibacterial agents such as Vancomycin, Daptomycin, Ceftaroline Fosamil, Tetracycline, Clindamycine, and Tedizolid phosphate are available in the market for treatment of infections associated with MRSA. According to the Centers for Disease Control and Prevention (CDC) review 2015, around 33% people globally had Staphylococcus aureus (S. aureus) bacteria in their nose, usually without any illness.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1538

Market players are focused on developing and launching new drugs containing antibacterial agents for treating infections associated with MRSA. For instance, in 2018, Destiny Pharma Inc., received investigational new drug application from the U.S. FDA for Exeporfinium Chloride (XF-73), a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections by methicillin-resistant staphylococcus aureus (MRSA). The study is estimated to be completed by December 2019.

The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to be valued at US$ 984.6 million in 2020, and is expected to register a CAGR of 4.4% during the forecast period (2020–2027).

Figure 1. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Share (%) in Terms of Value, By Region, 2020

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Research Report: https://bit.ly/3shttYa

Increasing Regulatory Approvals for Drugs Is Expected to Drive the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Growth

Approvals and launches of affordable generic medication is expected to drive the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market growth over the forecast period. For instance, in 2015, Glenmark Pharmaceuticals received the approval from the U.S. Food and Drug Administration (FDA) for the generic version of the anti-bacterial drug, Zyvox. Moreover, in 2015, Allergan Plc. received the U.S. FDA approval for supplemental new drug application (sNDA) to update the label of Teflaro (ceftaroline fosamil) for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP).

Furthermore, strategic agreements and collaborations by market players regarding distribution of MRSA drugs are expected to drive the market growth. For instance, in 2016, Basilea Pharmaceutica Ltd. entered into a supply, distribution, and license agreement with Grupo Biotoscana S.L., for Basilea’s antifungal CRESEMBA (isavuconazole) and antibiotic Zevtera (ceftobiprole) in 19 countries of Latin America along with Brazil, Mexico, Argentina, and Colombia.

However, declining patient pool having infections caused by MRSA pathogen is expected to restrain growth of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. According to the Centers for Disease Control and Prevention, hospital associated MRSA infections declined by 54% between 2005 and 2011 owing to increasing awareness about personal and public hygiene among the populace. This, in turn, is expected to reduce demand for the drugs.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-surpass-us-13-billion-by-2026-2485

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Regional Analysis

Regional segmentation of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among region, North America is expected to hold a dominant position in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market, and is expected to witness significant growth over the forecast period, owing to increasing health awareness, favorable reimbursement scenario, rising healthcare expenditure, and increasing number of approvals and launches of MRSA drugs. For instance, in 2016, Allergan Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) to update the label for Dalvance (dalbavancin) for injection.

Moreover, Asia Pacific is expected to witness significant growth over the forecast period, owing to a larger patient pool, and expansion strategies adopted by players to increase their market presence. For instance, in 2017, Basilea Pharmaceutica Ltd. entered a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea’s antibiotic Zevtera, a broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao.

Furthermore, Europe is projected to witness significant market growth owing to launch and approval of new drugs. For instance, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1538

Figure 2. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Share (%), by Drug Class, 2020

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitive Landscape

Key players operating in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include Merck & Co, Inc., Pfizer, Inc., Allergan Plc., Teva Pharmaceutical Industries ltd, Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International S.A., and Innovation Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • CKD Stages Treatment Options
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Pipeline Analysis
   • Market Trends
   • Recent Product Launch/Approvals
   • Cost of Treatment
   • Regulatory Scenario
   • PEST Analysis
   • Mergers, Acquisitions, and Partnerships
   • Epidemiology
   • Brilacidin Effectiveness
   • Brilacidin Research Perspective
   • Reimbursement Scenario (Medicare Part D Spending)
4. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
   • Economic Impact
   • Supply and Demand Analysis
   • Research and Development
   • Government Initiatives
5. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug Class, 2016 – 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Glycopeptides and Lipoglycopeptides
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Oxazolidinones
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Lipopeptides
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Cephalosporin
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Tetracycline
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
6. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
7. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Region, 2016 – 2027, (US$ Mn)
   • Introduction
     • Market Share Analysis, By Region, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, For Regions, 2017–2027
   • North America
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Europe
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • Germany
       • U.K.
       • France
       • Italy
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • China
       • India
       • Japan
       • Australia
       • South Korea
       • ASEAN
       • Rest of Asia Pacific
   • Middle East
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
     • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
       • South Africa
       • Central Africa
       • North Africa
8. Competitive Landscape
   • Heat Map Analysis
   • Company Profiles
9. Section
   • Research Methodology
   • About us and Sales Contact

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837